×

Stocks Eli Lilly and Co

  • woman_in_rain.jpg

    Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals and Cell Genesys, much lower. After the closing bell Tuesday, Bristol-Myers Squibb and Pfizer had an announcement to make...

  • graphic_word_ofthe_street.jpg

    The dollar rose and the Dow edged higher on Tuesday as optimism about consumer confidence overcame fresh worries about the flagging U.S. economy.

  • Byetta Needle

    After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?

  • As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)

  • It was my turn to man the CNBC Alerts Desk earlier today from 9am ET to 1 pm ET. I had finished blogging about the "Barron's bounce" Amylin Pharmaceuticals was getting, based on the speculative mention about it being a potential takeout target for Eli Lilly. Then, I look up at the screen and see AMLN is absolutely tanking...

  • Amylin

    U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.

  • Flumist Advertisement

    Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?

  • graphic_word_ofthe_street.jpg

    The Dow fell by triple digits on Tuesday as worries about further losses stemming from the mortgage crisis moved back into the spotlight.

  • graphic_fast_money.jpg

    The boss at Eli Lilly offers his diagnosis on Big Pharma's prospects.

  • Cramer offers up five reasons why this sector is the best one to own through the fall. Plus, the top stocks in the group.

  • Elan

    The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.

  • Lilly

    In the latest move in the big pharma restructuring/outsourcing trend, Eli Lilly announced this morning that it's selling a lab site in its home state of Indiana to the contract research organization Covance.

  • What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.

  • Stocks ended sharply lower Thursday as the market got a triple whammy: Oil resumed its ascent, major earnings reports sparked a fresh wave of concern about corporate profits and home sales hit a 10-year low. All three major indexes lost at least  2 percent.

  • Stocks declined as oil resumed its ascent and investors braced for the next batch of corporate earnings.  A drop in home sales and a jump in jobless claims above the key 400,000 mark added some pressure.

  • Stocks declined as oil resumed its ascent and investors braced for the next batch of corporate earnings.  A drop in home sales and a jump in jobless claims above the key 400,000 mark added some pressure.

  • On Squawk Box this morning, CEOs from various industries aired their insights on the economy, energy prices, real estate and politics.

  • cialis_package.jpg

    So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs. I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.

  • Stocks declined as oil resumed its ascent and investors braced for the next batch of corporate earnings.  A drop in home sales and a jump in jobless claims above the key 400,000 mark added some pressure.

  • Bristol-Myers Squibb on Thursday posted quarterly earnings that beat forecasts, helped by higher sales of blood clot preventer Plavix and schizophrenia treatment Abilify, and the company announced an additional $1 billion in planned cost cuts.